The gut microbiota in multiple sclerosis varies with disease activity.
Florence ThirionFinn SellebjergYong FanLiwei LyuTue H HansenNicolas PonsFlorence LevenezBenoit QuinquisEvelina StankevicHelle B SøndergaardThomas M DantoftCasper S PoulsenSofia K ForslundHenrik VestergaardTorben HansenSusanne BrixAnnette OturaiPer Soelberg SørensenStanislav D EhrlichOluf PedersenPublished in: Genome medicine (2023)
Considerable aberrations are present in the gut microbiota of patients with multiple sclerosis that are directly associated with blood biomarkers of inflammation, and in treatment-naïve cases bacterial richness is positively associated with disease activity. Yet, the finding of two symbiotic bacterial species in non-disease-active cases that produce favorable immune-modulating compounds provides a rationale for testing these bacteria as adjunct therapeutics in future clinical trials.
Keyphrases
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- clinical trial
- rheumatoid arthritis patients
- multiple sclerosis
- ankylosing spondylitis
- juvenile idiopathic arthritis
- oxidative stress
- small molecule
- signaling pathway
- white matter
- combination therapy
- phase ii
- open label
- genetic diversity
- dna methylation